248 related articles for article (PubMed ID: 37487714)
1. Relapse of neurosymptomatic cerebrospinal fluid HIV RNA escape.
Chan TY; Marta M; Rackstraw S
HIV Med; 2023 Nov; 24(11):1158-1163. PubMed ID: 37487714
[TBL] [Abstract][Full Text] [Related]
2. The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series.
Chan TY; De Zan V; Gregg A; Alagaratnam J; Gerevini S; Antinori A; D'Arminio Monforte A; Saracino A; Trunfio M; Everitt A; Rackstraw S; Marta M; Calcagno A; Cinque P; Winston A
AIDS; 2021 Nov; 35(14):2341-2346. PubMed ID: 34127578
[TBL] [Abstract][Full Text] [Related]
3. Minimal detection of cerebrospinal fluid escape after initiation of antiretroviral therapy in acute HIV-1 infection.
Handoko R; Chan P; Jagodzinski L; Pinyakorn S; Ubolyam S; Phanuphak N; Sacdalan C; Kroon E; Dumrongpisutikul N; Paul R; Valcour V; Ananworanich J; Vasan S; Spudich S;
AIDS; 2021 Apr; 35(5):777-782. PubMed ID: 33306551
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.
Peluso MJ; Ferretti F; Peterson J; Lee E; Fuchs D; Boschini A; Gisslén M; Angoff N; Price RW; Cinque P; Spudich S
AIDS; 2012 Sep; 26(14):1765-74. PubMed ID: 22614889
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal Fluid HIV-1 Escape in Patients With Neurocognitive Symptoms: Pooled Data From a Neuro-HIV Platform and the NAMACO Study.
Filippidis P; Damas J; Viala B; Assal F; Nawej Tshikung O; Tarr P; Derfuss T; Oberholzer M; Jelcic I; Hundsberger T; Sacco L; Cavassini M; Du Pasquier R; Darling KEA;
J Acquir Immune Defic Syndr; 2023 Jul; 93(3):219-228. PubMed ID: 36927958
[TBL] [Abstract][Full Text] [Related]
6. Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells.
Joseph SB; Kincer LP; Bowman NM; Evans C; Vinikoor MJ; Lippincott CK; Gisslén M; Spudich S; Menezes P; Robertson K; Archin N; Kashuba A; Eron JJ; Price RW; Swanstrom R
Clin Infect Dis; 2019 Sep; 69(8):1345-1352. PubMed ID: 30561541
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid viral escape in HIV patients on antiretroviral therapy: A systematic review of reported cases.
Nyondo GG; Njiro BJ; Bwire GM
Rev Med Virol; 2024 May; 34(3):e2536. PubMed ID: 38578230
[TBL] [Abstract][Full Text] [Related]
8. Learning from cerebrospinal fluid drug-resistant HIV escape-associated encephalitis: a case report.
Kang J; Wang Z; Zhou Y; Wang W; Wen Y
Virol J; 2023 Dec; 20(1):292. PubMed ID: 38072961
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects.
Pérez-Valero I; Ellis R; Heaton R; Deutsch R; Franklin D; Clifford DB; Collier A; Gelman B; Marra C; McCutchan JA; Navis A; Sacktor N; Simpson D; Grant I; Letendre S
AIDS; 2019 Mar; 33(3):475-481. PubMed ID: 30702516
[TBL] [Abstract][Full Text] [Related]
10. Relapse of Symptomatic Cerebrospinal Fluid HIV Escape.
Ferretti F; De Zan V; Gerevini S; Turrini F; Boeri E; Gianotti N; Hasson H; Lazzarin A; Cinque P
Curr HIV/AIDS Rep; 2020 Oct; 17(5):522-528. PubMed ID: 32875516
[TBL] [Abstract][Full Text] [Related]
11. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study.
Livelli A; Vaida F; Ellis RJ; Ma Q; Ferrara M; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Grant I; Letendre SL;
Lancet HIV; 2019 Jul; 6(7):e456-e462. PubMed ID: 31208949
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid virology in people with HIV.
Henderson M; Pepper N; Bawa M; Muir D; Everitt A; Mackie NE; Winston A
HIV Med; 2023 Jul; 24(7):838-844. PubMed ID: 36895097
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid HIV RNA in persons living with HIV.
Di Carlofelice M; Everitt A; Muir D; Winston A
HIV Med; 2018 May; 19(5):365-368. PubMed ID: 29368400
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.
Edén A; Fuchs D; Hagberg L; Nilsson S; Spudich S; Svennerholm B; Price RW; Gisslén M
J Infect Dis; 2010 Dec; 202(12):1819-25. PubMed ID: 21050119
[TBL] [Abstract][Full Text] [Related]
15. Two treatment strategies for management of Neurosymptomatic cerebrospinal fluid HIV escape in Pune, India.
Dravid AN; Gawali R; Betha TP; Sharma AK; Medisetty M; Natrajan K; Kulkarni MM; Saraf CK; Mahajan US; Kore SD; Rathod NM; Mahajan US; Letendre SL; Wadia RS; Calcagno A
Medicine (Baltimore); 2020 Jun; 99(24):e20516. PubMed ID: 32541474
[TBL] [Abstract][Full Text] [Related]
16. Temporal Patterns and Drug Resistance in CSF Viral Escape Among ART-Experienced HIV-1 Infected Adults.
Mukerji SS; Misra V; Lorenz D; Cervantes-Arslanian AM; Lyons J; Chalkias S; Wurcel A; Burke D; Venna N; Morgello S; Koralnik IJ; Gabuzda D
J Acquir Immune Defic Syndr; 2017 Jun; 75(2):246-255. PubMed ID: 28328546
[TBL] [Abstract][Full Text] [Related]
17. Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study.
Edén A; Nilsson S; Hagberg L; Fuchs D; Zetterberg H; Svennerholm B; Gisslén M
J Infect Dis; 2016 Dec; 214(12):1822-1825. PubMed ID: 27683820
[TBL] [Abstract][Full Text] [Related]
18. Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV.
Trunfio M; Rugge W; Mighetto L; Vai D; Atzori C; Nigra M; Domini S; Borgogno E; Guastamacchia G; Bonora S; Di Perri G; Calcagno A
AIDS; 2020 Nov; 34(13):1899-1906. PubMed ID: 32701580
[TBL] [Abstract][Full Text] [Related]
19. CSF Inflammation Markers Associated with Asymptomatic Viral Escape in Cerebrospinal Fluid of HIV-Positive Individuals on Antiretroviral Therapy.
Guha D; Misra V; Yin J; Gabuzda D
Viruses; 2023 Aug; 15(9):. PubMed ID: 37766236
[TBL] [Abstract][Full Text] [Related]
20. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy.
Dahl V; Lee E; Peterson J; Spudich SS; Leppla I; Sinclair E; Fuchs D; Palmer S; Price RW
J Infect Dis; 2011 Dec; 204(12):1936-45. PubMed ID: 22021620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
